Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer

NCT03396497 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: LYC-55716
DRUG: Pembrolizumab

Sponsor

Lycera Corp.